The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry,reverse transcription and integration

Barré-Sinoussi F. , Chermann J.C. , Rey F. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868–871.

Stolk L.M. , Luers J.F. Increasing number of anti-HIV drugs but no definite cure. Review of anti-HIV drugs. Pharm World Sci 2004; 26: 133–136.

Chun T.W. , Stuyver L. , Mizell S.B. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94: 13193–13197.

Clavel F. , Hance A.J. HIV drug resistance. N Engl J Med 2004; 350: 1023–1035.

Miller M.D. , Farnet C.M. , Bushman F.D. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71: 5382–5390.

Emery S. , Winston A. Raltegravir: a new choice in HIV and new chances for research. Lancet 2009; 374: 764–766.

Brody E.N. , Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000; 74: 5–13.

Gold L. , Brown D. , He Y. , Shtatland T. , Singer B.S. , Wu Y. From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops. Proc Natl Acad Sci U S A 1997; 94: 59–64.

Schneider D.J. , Feigon J. , Hostomsky Z. , Gold L. High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995; 34: 9599–9610.

Pileur F. , Andreola M.L. , Dausse E. Selective inhibitory DNA aptamers of the human RNase H1. Nucleic Acids Res 2003; 31: 5776–5788.

Kensch O. , Connolly B.A. , Steinhoff H.J. , McGregor A. , Goody R.S. , Restle T. HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem 2000; 275: 18271–18278.

DeStefano J.J. , Nair G.R. Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase. Oligonucleotides 2008; 18: 133–144.

DeStefano J.J. , Cristofaro J.V. Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity. Nucleic Acids Res 2006; 34: 130–139.

Joshi P. , Prasad V.R. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 2002; 76: 6545–6557.

Tuerk C. , MacDougal-Waugh S. In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins. Gene 1993; 137: 33–39.

Marozzi A. , Meneveri R. , Giacca M. , Gutierrez M.I. , Siccardi A.G. , Ginelli E. In vitro selection of HIV-1 TAR variants by the Tat protein. J Biotechnol 1998; 61: 117–128.

Métifot M. , Leon O. , Tarrago-Litvak L. , Litvak S. , Andreola M.L. Targeting HIV-1 integrase with aptamers selected against the purified RNase H domain of HIV-1 RT. Biochimie 2005; 87: 911–919.

Allen P. , Worland S. , Gold L. Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool. Virology 1995; 209: 327–336.

Jing N. , De Clercq E. , Rando R.F. Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design. J Biol Chem 2000; 275: 3421–3430.

Andreola M.L. , Pileur F. , Calmels C. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 2001; 40: 10087–10094.

Phan A.T. , Kuryavyi V. , Ma J.B. , Faure A. , Andreola M.L. , Patel D.J. An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc Natl Acad Sci U S A 2005; 102: 634–639.

de Soultrait V.R. , Lozach P.Y. , Altmeyer R. , Tarrago-Litvak L. , Litvak S. , Andreola M.L. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J Mol Biol 2002; 324: 195–203.

Ojwang J.O. , Buckheit R.W. , Pommier Y. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39: 2426–2435.

Esté J.A. , Cabrera C. , Schols D. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol Pharmacol 1998; 53: 340–345.

Métifot M. , Faure A. , Guyonnet-Duperat V. Cellular uptake of ODNs in HIV-1 human-infected cells: a role for viral particles in DNA delivery? Oligonucleotides 2007; 17: 151–165.

Charneau P. , Mirambeau G. , Roux P. , Paulous S. , Buc H. , Clavel F. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994; 241: 651–662.

Ventura M. , Tarrago-Litvak L. , Dolle V. Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions. Arch Virol 1999; 144: 513–523.

Brussel A. , Mathez D. , Broche-Pierre S. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS 2003; 17: 645–652.

Baba M. , Pauwels R. , Balzarini J. , Arnout J. , Desmyter J. , De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 1988; 85: 6132–6136.

D'Andrea G. , Brisdelli F. , Bozzi A. AZT: an old drug with new perspectives. Curr Clin Pharmacol 2008; 3: 20–37.

Schultze P. , Macaya R.F. , Feigon J. Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG). J Mol Biol 1994; 235: 1532–1547.

Dollé V. , Fan E. , Nguyen C.H. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J Med Chem 1995; 38: 4679–4686.

Reigadas S. , Andreola M.L. , Wittkop L. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother 2010; 65: 434–437.

Neidle S. The structures of quadruplex nucleic acids and their drug complexes. Curr Opin Struct Biol 2009; 19: 239–250.

Tan J.H. , Gu L.Q. , Wu J.Y. Design of selective G-quadruplex ligands as potential anticancer agents. Mini Rev Med Chem 2008; 8: 1163–1178.

Patel D.J. , Phan A.T. , Kuryavyi V. Human telomere, oncogenic promoter and 5′-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res 2007; 35: 7429–7455.

Wu Y. The second chance story of HIV-1 DNA: unintegrated? Not a problem! Retrovirology 2008; 5: 61.

Zhu K. , Dobard C. , Chow S.A. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004; 78: 5045–5055.

Hehl E.A. , Joshi P. , Kalpana G.V. , Prasad V.R. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J Virol 2004; 78: 5056–5067.

Buckheit R.W. Jr. , Watson K.M. , Morrow K.M. , Ham A.S. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res 2010; 85: 142–158.